echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Ann Rheum Dis: Severe new crown pneumonia inflammatory storm sarilumab uses sarilumab to block the efficacy of interleukin-6.

    Ann Rheum Dis: Severe new crown pneumonia inflammatory storm sarilumab uses sarilumab to block the efficacy of interleukin-6.

    • Last Update: 2020-07-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The study was designed to assess the safety and efficacy of using blocking interleukin in patients with severe neo-coronary pneumonia associated with systemic inflammatory stormsAn open label study was conducted on patients with severe new coronary pneumonia associated with an over-inflammatory response (an increase in inflammatory markers and serum levels)In addition to standard treatment, additional intravenous injections are provided and the results are compared to matching patients who receive only standard treatmentAssess clinical improvement, mortality, safety, and reaction predictors on the first dayPatients who received treatment were only treated with standard treatment and were used as a control groupOn the first day of follow-up, % of the treated patients had clinical improvement and % of the patients diedThese findings showed no significant difference from the control group (clinical improvement rate % mortality % ;)The baseline ratio and the scanned pulmonary reality% can predict clinical improvement in the treatment of patientsPatients with pulmonary reality % used a median time (days) of treatment that achieved clinical improvement shorter than the standard treatment (days;)The infection rates were similar to those of the two groupsThere was no significant difference between the overall clinical improvement rate and mortality rate of patients with severe new coronary pneumonia and standard treatmentIn the subgroup of patients with mild baseline pulmonary reality was associated with faster recovery
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.